BEML PAT falls 31% YoY to ₹33 Cr despite 42% revenue growth; QoQ swing from loss to profit
PAT -30.6% YoY · revenue +42% · margins compressing
₹1,191.61 Cr
+42% YoY
₹33.34 Cr
-30.6% YoY
2.78%
-2.9pp YoY
₹4
BEML's consolidated PAT came in at ₹33.34 Cr for Q2 FY27, down 30.6% from ₹48.03 Cr in the year-ago quarter, even though consolidated revenue jumped 42.0% YoY to ₹1,191.61 Cr from ₹839.09 Cr — profit trailing revenue YoY means this quarter's story is margin compression, not growth. Sequentially it looks better: the company swung from a ₹27.01 Cr consolidated loss in Q1 FY27 to this quarter's profit, on a 45.4% QoQ revenue jump. Standalone PAT of ₹32.93 Cr (EPS ₹3.95) tracks closely with the consolidated print (EPS ₹4.00), so both bases tell the same story. No exceptional items appear in the current, sequential or year-ago columns, so both the YoY decline and the QoQ turnaround are purely operational, not one-off driven.
Q2 FY-2027 vs prior quarters
Net profit margin compressed to 2.80% from 5.68% a year ago (even as it improved from -3.29% in Q1). The squeeze sits on the cost-of-materials line: material and bought-out cost rose to 60.8% of revenue from 56.9% a year ago, offsetting a drop in employee costs to 18.3% of revenue from 24.3% as fixed costs spread over a larger revenue base. On an EBITDA basis (PBT plus finance cost and depreciation), the margin works out to roughly 7.2% of revenue this quarter — well short of the "sustainable 16% EBITDA margin" management guided to on the Q1 FY27 call, so on profitability the quarter missed the bar management itself set even as revenue outpaced it.
The stock went into the print at ₹2,052.5, up 0.5% over the past month of trading.
Management projected sustainable EBITDA margins of 16% with a breakeven at ₹4,000 Cr revenue. Actual Q1 FY-2027 delivered 0.2% OPM and -3.3% NPM (₹27 Cr loss). Order book target of ₹24,000 Cr by year-end (from ₹15,900 Cr base + ₹6,000+ Cr inflow) stated; capex and R&D at all-time highs.
— This quarter: missed
Management's Q1 FY27 commentary had flagged a negative short-term outlook, a concerned tone, and pegged EBITDA breakeven near ₹4,000 Cr of annualised revenue — H1 FY27 consolidated revenue of ₹2,011 Cr (annualising to ~₹4,022 Cr) sits right at that threshold, yet margins remain far below the stated 16% target. Separately, the Chairman had guided to roughly 30% revenue growth for FY27; H1 revenue is up 35.1% YoY, tracking ahead of that goal even as the margin promise lags. No analyst consensus estimate for this specific quarter turned up in a search (results were declared the same day, so previews had not yet circulated), so vsStreet is unknown; no company press release was available in the context to cross-check management's own framing. On orders, the quarter saw a ₹5,400 Cr NHSRCL rolling-stock win (Sep 18) and a ₹75.58 Cr HMV export order (Oct 9), building toward the ₹24,000 Cr FY27-end order-book target flagged off a ~₹15,900-16,284 Cr base — though this filing carries no consolidated order-book total (segment disclosure is MCA-exempted), so the exact progress figure can't be confirmed from the result itself.
W1
Whether EBITDA margin (~7.2% this quarter) closes the gap to management's guided 'sustainable 16%' target in coming quarters
W2
Order-book progress toward the stated ₹24,000 Cr FY27 year-end target (from the ~₹15,900-16,284 Cr base cited post-Q1)
W3
Whether Q2's QoQ revenue/profit recovery (after Q1's loss) sustains into Q3 FY27 or proves a one-quarter bounce
Source figures in ₹ Lakh, converted ÷100 to ₹ Cr; no exceptional items in current, sequential, or year-ago columns on either basis; standalone PAT ₹32.93 Cr vs consolidated ₹33.34 Cr is a <2% divergence (consolidated includes ₹0.01 Cr NCI share); scan is clean and legible, column headers unambiguous.
Informational and educational content only. Not investment advice.